Alere flu test wins first CLIA waiver for new nucleic acid assay
This article was originally published in Clinica
Executive Summary
Alere’s i Influenza A & B test has gained what FDA says is the first Clinical Laboratory Improvements Amendments (CLIA) waiver for a nucleic acid-based diagnostic. The approval marks an important milestone for moving molecular diagnostics into a greater variety of healthcare settings beyond sophisticated labs.